Heartseed Inc. develops and commercializes iPS cell-derived cardiomyocyte replacement therapy for heart failure. The company’s lead product is HS-001 for heart failure with reduced ejection fraction indications, including dilated cardiomyopathy, old myocardial infraction, and dilated phase of hypertrophic cardiomyopathy. It also develops products using autologous iPSC and HLA knock-out iPSC. In addition, the company offers differentiation induction, mass culture, purification, and myocardial globule production technology. The company was incorporated in 2015 and is headquartered in Tokyo, Japan.
Metrics to compare | 219A | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship219APeersSector | |
|---|---|---|---|---|
P/E Ratio | 72.2x | −10.3x | −0.4x | |
PEG Ratio | 0.48 | −0.11 | 0.00 | |
Price/Book | 5.7x | 3.9x | 2.6x | |
Price / LTM Sales | 14.1x | 37.9x | 3.2x | |
Upside (Analyst Target) | 112.9% | 96.2% | 49.0% | |
Fair Value Upside | Unlock | 1.5% | 6.8% | Unlock |